Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
Partnering with Sonnet
Sonnet is actively engaging with potential partners and licensees interested in leveraging the strength of our proprietary FHAB technology platform.
We invite interested parties to contact us via the link below.
Contact Sonnet